Work

Induction of systemic anti-melanoma immunity through intratumoral TLR-7/8 activation

Year: 2014

Type: article

Abstract: Meeting abstracts Intratumoral immune activation can induce systemic immunity and anti-tumor activity. Imiquimod is a cream-formulated, TLR-7 agonist that is FDA-approved for the treatment of non-melanoma skin cancers, but has limited activity against melanoma. In the current study, we studied the

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-2-s3-p176

Authors: Manisha Singh, Hiep Khong, Zhimin Dai, John P Vasilakos, Patrick Hwu, Willem W Overwijk

Institutions: The University of Texas MD Anderson Cancer Center, 3M (United States), Kindeva Drug Delivery (United States)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490